Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Lim

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
ESMO Open|February 25, 2025
PALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350+5G>A variant in 3987 Korean cancer patientsM-C Kang, S Lee, H Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
The Lancet Regional Health. Western Pacific|February 9, 2024
Age-specific breast and ovarian cancer risks associated with germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic variants - an Asian study of 572 familiesWeang-Kee Ho, Nur Tiara Hassan, Sook-Yee Yoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Predicting the Likelihood of Carrying a <i>BRCA1</i> or <i>BRCA2</i> Mutation in Asian Patients With Breast CancerBoon Hong Ang, Weang Kee Ho, Eldarina Wijaya, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
ESMO Open|February 25, 2025
PALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350+5G>A variant in 3987 Korean cancer patientsM-C Kang, S Lee, H Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
The Lancet Regional Health. Western Pacific|February 9, 2024
Age-specific breast and ovarian cancer risks associated with germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic variants - an Asian study of 572 familiesWeang-Kee Ho, Nur Tiara Hassan, Sook-Yee Yoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Predicting the Likelihood of Carrying a <i>BRCA1</i> or <i>BRCA2</i> Mutation in Asian Patients With Breast CancerBoon Hong Ang, Weang Kee Ho, Eldarina Wijaya, et al.
Pageof 5